HGF/c‐Met Axis‐Targeted Nanotherapy via GSH‐Responsive Polymer Platforms Suppresses Uveal Melanoma Metastasis
Advanced Healthcare Materials · 2025-06 · 14 (15)
DOI: 10.1002/adhm.202405056 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Healthcare Materials, online erschienen am 08.05.2025. Verfasst von Hui Tao und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, The Third Xiangya Hospital, Central South University, Changsha, Hunan, 410013, P. R. China. Hauptthemen laut MEDLINE: Uveal Neoplasms, Proto-Oncogene Proteins c-met, Melanoma, Nanoparticles. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Uveal melanoma (UM), a malignant tumor originating within the ocular, characterizes high metastasis and lethality among patients. Cancer stem cells (CSCs) distinguished by the c‐Met protein are believed to mediate tumor metastasis in UM. However, the low bioavailability of c‐Met inhibitors like Crizotilib (Criz) limits their clinical application. Herein, a GSH‐responsive nanoparticle named NP @Oxa/Criz to precisely deliver Criz and Oxaliplatin (Oxa) is synthesized in this study. The dual‐action mechanism of NP @Oxa/Criz inhibits the HGF/c‐Met axis to prevent the nuclear translocation of β‐Catenin, thereby reducing the transcription of metastasis‐associated genes and undermining the stemness and metastasis of UM cells. Simultaneously, NP @Oxa/Criz induces immunogenic cell death to boost anti‐tumor immunity. In vivo studies demonstrate that NP @Oxa/Criz can accumulate in tumor sites, significantly eradicating the primary UM in the ocular and suppressing the metastasis UM in the liver and peritoneal. The outcomes from this work illuminate the therapeutic mechanisms of NP @Oxa/Criz and provide a precise and potent nanotherapeutic strategy for clinical treatment and research in highly metastatic UM.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Ophthalmology, The Third Xiangya Hospital, Central South University, Changsha, Hunan, 410013, P. R. China.
- Chinese Academy of Sciences, Beijing, 100049, China.
- Beijing National Laboratory for Molecular Sciences, State Key Laboratory of Polymer Physics and Polymer Chemistry, Institute of Chemistry, Chinese Academy of Sciences, Beijing, 100190, P. R. China.
ORCID-Profile: Zhihong Deng
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Tao, H., Liu, H., Zhang, H., Ren, H., Wen, B., Zhang, J., Du, J., Cai, Z., & Deng, Z. (2025). HGF/c‐Met Axis‐Targeted Nanotherapy via GSH‐Responsive Polymer Platforms Suppresses Uveal Melanoma Metastasis. Advanced Healthcare Materials, 14(15). https://doi.org/10.1002/adhm.202405056
Vancouver
Tao H, Liu H, Zhang H, Ren H, Wen B, Zhang J, et al. HGF/c‐Met Axis‐Targeted Nanotherapy via GSH‐Responsive Polymer Platforms Suppresses Uveal Melanoma Metastasis. Advanced Healthcare Materials. 2025;14(15). doi:10.1002/adhm.202405056
BibTeX
@article{Tao2025,
author = {Tao, Hui and Liu, Hanhan and Zhang, Hanchen and Ren, Hong and Wen, Binyu and Zhang, Jing and Du, Jiaqi and Cai, Ziyi and Deng, Zhihong},
title = {HGF/c‐Met Axis‐Targeted Nanotherapy via GSH‐Responsive Polymer Platforms Suppresses Uveal Melanoma Metastasis},
journal = {Advanced Healthcare Materials},
year = {2025},
volume = {14},
number = {15},
doi = {10.1002/adhm.202405056}
}
EUVIMED